Animal models of Parkinson's disease progression

被引:177
|
作者
Meredith, Gloria E. [1 ]
Sonsalla, Patricia K. [2 ]
Chesselet, Marie-Francoise [3 ]
机构
[1] Rosalind Franklin Univ Med & Sci, Dept Mol & Cellular Pharmacol, N Chicago, IL 60064 USA
[2] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurol, Piscataway, NJ 08854 USA
[3] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA
关键词
substantia nigra; MPTP; 6-OHDA; rotenone; LPS; engrail; alpha-synuclein;
D O I
10.1007/s00401-008-0350-x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Parkinson's disease (PD) is a progressive neurodegenerative disorder whose etiology is not understood. This disease occurs both sporadically and through inheritance of single genes, although the familial types are rare. Over the past decade or so, experimental and clinical data suggest that PD could be a multifactorial, neurodegenerative disease that involves strong interactions between the environment and genetic predisposition. Our understanding of the pathophysiology and motor deficits of the disease relies heavily on fundamental research on animal models and the last few years have seen an explosion of toxin-, inflammation-induced and genetically manipulated models. The insight gained from the use of such models has strongly advanced our understanding of the progression and stages of the disease. The models have also aided the development of novel therapies to improve symptomatic management, and they are critical for the development of neuroprotective strategies. This review critically evaluates these in vivo models and the roles they play in mimicking the progression of PD.
引用
收藏
页码:385 / 398
页数:14
相关论文
共 50 条
  • [41] Mitochondrial Dysfunction in Genetic Animal Models of Parkinson's Disease
    Trancikova, Alzbeta
    Tsika, Elpida
    Moore, Darren J.
    ANTIOXIDANTS & REDOX SIGNALING, 2012, 16 (09) : 896 - 919
  • [42] Cardiovascular Autonomic Dysfunction in Animal Models of Parkinson's Disease
    Fleming, Sheila M.
    JOURNAL OF PARKINSONS DISEASE, 2011, 1 (04) : 321 - 327
  • [43] Neuroprotection by immunomodulatory agents in animal models of Parkinson's disease
    Bridget Martinez
    Philip V.Peplow
    Neural Regeneration Research, 2018, 13 (09) : 1493 - 1506
  • [44] Neuroprotective Effects of Temsirolimus in Animal Models of Parkinson’s Disease
    Rosalba Siracusa
    Irene Paterniti
    Marika Cordaro
    Rosalia Crupi
    Giuseppe Bruschetta
    Michela Campolo
    Salvatore Cuzzocrea
    Emanuela Esposito
    Molecular Neurobiology, 2018, 55 : 2403 - 2419
  • [45] Estrogen and SERM neuroprotection in animal models of Parkinson's disease
    Morissette, Marc
    Al Sweidi, Sara
    Callier, Sophie
    Di Paolo, Therese
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2008, 290 (1-2) : 60 - 69
  • [46] Evaluation of animal models of Parkinson's disease for neuroprotective strategies
    Emborg, ME
    JOURNAL OF NEUROSCIENCE METHODS, 2004, 139 (02) : 121 - 143
  • [47] Evaluation of motor disorders in animal models of Parkinson's disease
    Campos-Romo, A.
    REVISTA DE NEUROLOGIA, 2008, 46 (03) : 167 - 174
  • [48] Parkinson's disease: animal models and dopaminergic cell vulnerability
    Blesa, Javier
    Przedborski, Serge
    FRONTIERS IN NEUROANATOMY, 2014, 8
  • [49] Neuroprotection by estrogen in animal models of ischemia and Parkinson's disease
    Merchenthaler, I
    Shughrue, PJ
    DRUG DEVELOPMENT RESEARCH, 2005, 66 (02) : 172 - 181
  • [50] Exploring the Peripheral Initiation of Parkinson's Disease in Animal Models
    Sorrentino, Zachary A.
    Giasson, Benoit I.
    NEURON, 2019, 103 (04) : 547 - 549